Vitamin A is an essential nutrient, for which there is a slightly increased requirement during the third trimester of pregnancy, with even greater requirements for lactating women. Serum retinol levels decline during pregnancy, especially during the third trimester, followed by a rapid increase postpartum. Hemodilution and inadequate nutritional status contribute to this pattern. Night-blindness is more common in the third trimester of pregnancy, and night-blind pregnant women have lower mean serum retinol concentrations. Increased morbidity is associated with night-blindness in women, especially during pregnancy. Vitamin A supplementation during pregnancy in deficient populations reduces night-blindness, low serum retinol levels, and nutritional anemia during pregnancy and substantially reduces maternal postpartum infections. A substantial reduction in maternal mortality has been observed in malnourished vitamin A-deficient women following vitamin A or β-carotene supplementation. Infant cord blood retinol and birthweight appear to be resistant to maternal supplementation with vitamin A during pregnancy. No studies have reported an impact of maternal vitamin A supplementation on neonatal morbidity or mortality.
Introduction
Vitamin A is an essential nutrient because of its important roles in vision, cellular differentiation, embryonic development, reproduction, growth, and the immune system [1] . The need for vitamin A is particularly critical during periods of rapid growth and tissue develop-ment, such as occur in pregnancy and early childhood; however, it is known that excessive doses of vitamin A, particularly in some forms, may be harmful. This report examines the evidence relating to the health benefits of vitamin A supplementation in pregnancy for both the mother and the newborn infant.
The report is divided into two main sections. In the first section, the biochemical forms of vitamin A and their physiological importance in pregnancy, lactation, and fetal development are examined. In the second, studies of the effects of vitamin A supplementation in pregnancy on maternal and newborn outcomes are examined. The recommendations identify opportunities for program development as well as areas for future research.
Metabolism of vitamin A in pregnancy and lactation
Vitamin A is a broad term used to describe a family of compounds, the parent of which is all-trans-retinol [1] . In addition to molecules derived from all-trans-retinol, provitamin A carotenoids, including β-carotene, that can be converted into all-trans-retinol are included in view of their biological activity [1] . Important derivates of all-trans-retinol include its aldehyde form (retinal), its acid form (retinoic acid), its storage form (retinyl palmitate), and its water-soluble form (β-glucuronide) [1] . Synthetic derivates of all-transretinol will also be discussed later in this report.
Absorption, transportation, and storage of vitamin A
Vitamin A in the form of retinyl esters and provitamin A carotenoids is absorbed from the small intestine during digestion following its release from food by proteolytic enzymes [1] . Bile and pancreatic enzymes hydrolyze these compounds, which are transported from micelles into the epithelia of the intestinal villi [1] . Cleavage of provitamin A carotenoids occurs within the intestinal villi to produce the retinal form of vitamin A [1, 2] . Retinal within the intestinal villi is bound to a cellular retinol-binding protein (CRBP-II), which can be reduced to bound retinol [1] . This retinyl ester, along with some unesterified retinol, is released into the lymph system within chylomicrons [1] .
The chylomicron remnants that result following hydrolysis within the plasma contain carotenoids and vitamin A, which are then taken up predominantly by liver parenchymal cells [1] . Within the liver, vitamin A is stored within the parenchymal cells, mostly as retinyl ester, but also in small quantities as retinol [1] . The other major cell type within the liver responsible for vitamin A storage is the stellate cell [1] . The parenchymal cell can transfer retinol to the stellate cell, which is the main storage site for vitamin A in the liver [1] . Vitamin A stored within the liver as retinyl ester is hydrolyzed to retinol and can then be released into the circulation when needed [1] . Upon release into the circulation, retinol is delivered to the tissues predominantly bound to retinol-binding protein (RBP) [2] . Little is known about the regulation of the release of retinol from the liver, although it is believed that homeostatic mechanisms control this process [1] .
Within cells, retinol is bound by cellular retinolbinding protein (CRPB), one exception being within the intestine, where it is bound to CRBP-II [1] . Similarly, retinoic acid is bound to cellular retinoic acidbinding protein (CRABP) or cellular retinal-binding protein (CRALBP) in the case of the eye [1] . Recently two sets of nuclear retinoic acid receptors have been discovered in tissues [1] . These receptors have provided new evidence on the role of vitamin A in cellular differentiation.
Units for measuring vitamin A intake
In this article, vitamin A is usually reported in either international units (IU) or retinol equivalents (RE). To convert international units derived from retinol to retinol equivalents, the value must be multiplied by 3.33 [3] . Because each system of measuring vitamin A makes different assumptions about the efficiency of metabolism of provitamin A sources to equivalent retinol intake, conversion cannot always be obtained exactly on the basis of a simple multiplication [2] . Occasionally vitamin A intake may also be expressed in micrograms (µg) or micromoles (µmol). Table 1 provides details of interconversions between each of these units.
Required and observed intakes of vitamin A
There is an increased need for vitamin A during pregnancy, although the additional amount is small and is limited to the third trimester. The level of vitamin A stored in the fetal liver is low and does not increase greatly if additional vitamin A supplements are given to the mother [4] . The 1988 recommended dietary intakes (RDI) of the Food and Agriculture Organization and the World Health Organization (FAO/WHO) defined two levels of intake, basal and safe levels, both of which assume an adequate total body reserve of vitamin A. The basal requirement is defined as the "average daily amount needed to prevent clinically demonstrable impairment of function," and the higher safe intake is sufficient for those few individuals with particularly high needs [5] . The recommended dietary intake levels have been formulated to ensure sufficient hepatic stores for three months in a 62-kg woman to allow for suboptimal intake and stress. An additional amount of 100 µg RE/day has been recommended as sufficient in pregnancy to meet the extra needs of the fetus without depleting maternal stores [5] . The total vitamin A needs of the fetus in the third trimester of pregnancy are estimated to be about 9% of total mean maternal stores of vitamin A [4] . For women who have adequate vitamin A stores and average long-term intakes of vitamin A above the safe level, no additional vitamin A intake is required during pregnancy.
The estimated vitamin A requirements of lactating women are higher than those of pregnant women. During the first six months of lactation, from 25% to 50% of a woman's total reserve of vitamin A (estimated as 206 mg) would be secreted in breastmilk [4] . To maintain maternal hepatic stores of vitamin A during lactation, an additional amount of 500 µg RE/day has been recommended during the first six months of lactation [5] and a slightly lesser amount for women lactating for longer than six months (+400 µg RE/day). Inadequate maternal stores of vitamin A will impair the transfer of vitamin A to the newborn through breastmilk. Table 2 compares the recommended dietary intakes of vitamin A in adult women and pregnant or lactating 
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Impact of vitamin A in pregnancy women from three different sources: FAO/WHO [5] , the United States [6] , and the United Kingdom [7] . The safe intake of FAO/WHO, the recommended dietary allowance (RDA) in the USA, and the upper reference nutrient intake in the UK all have similar definitions. These recommended intakes vary from 600 µg RE/day to 800 µg RE/day. Different definitions, and different assumptions about reference weights for adult women, may account for the variation between the lower levels for the FAO/WHO and the UK recommendations [1] . These recommended levels of nutrient intakes have been established for healthy individuals, but the need for vitamin A would be substantially increased in the presence of illness, especially febrile infectious illnesses, and conditions causing lipid malabsorption [1] . These conditions are often met in populations from developing countries, where infectious diseases in women and children, such as diarrhea, respiratory tract infections, malaria, and intestinal parasites, are all more prevalent than in industrialized countries and can contribute to increased vitamin A needs in these populations.
Studies of observed intakes of vitamin A from food in adult women have reported a median intake of 686 µg RE/day in the UK but higher intakes of 880 µg RE/day in the USA [8] . The mean observed intake of vitamin A in pregnant women in the USA has been reported as 1,200 µg RE/day [9] . In developing countries, seasonal variation in intakes of vitamin A can be considerable because of fluctuations in the availability of foods with high levels of bioavailable provitamin A carotenoids, such as fruits and vegetables. In industrialized countries, these fluctuations in vitamin A intake are less marked, because a higher proportion of vitamin A is derived from preformed vitamin A. Furthermore, the well-developed food market systems that make available preserved and processed foods that are often fortified with vitamin A provide access to a variety of vitamin A-rich foods throughout the year. Nonetheless, even in highly industrialized countries, some disadvantaged groups may exist with low levels of vitamin A intake [1] .
Changes in serum retinol during pregnancy
A large number of studies from both industrialized and developing countries have reported a pattern of declining serum retinol levels during pregnancy, especially in the third trimester, followed by a rapid increase postpartum . Only three studies have failed to report a similar pattern [31] [32] [33] . The findings from most of these studies are summarized in table 3. It should be noted that no attempt has been made to adjust the results based on the method used to assay vitamin A.
In the largest study [16] , there was a 9% drop in the average serum retinol values between the first and third trimesters, whereas in the longitudinal studies [12, 21, 29, 30] , there was an average decline of 14% in the serum retinol levels between the first and third trimesters. Five percent or less of women early in pregnancy have been reported to have serum retinol levels below 20 µg/dl [11, 36] , but this proportion increases up to 30% in the third trimester [11, 37] . Two main factors contribute to this pattern of declining serum retinol during pregnancy: hemodilution and nutritional status. As pregnancy progresses, hemodilution from an expanding blood volume contributes to the lowering of serum retinol levels, and the sudden reversal of this process following delivery leads to a rapid increase of serum retinol levels. Supporting this view is the observation that serum retinol does not change with gestation after adjustment with the corresponding hematocrit values [20] . In addition, the decline in serum retinol levels in the third trimester of pregnancy is of similar magnitude to the decline in serum albumin [23] and serum retinol-binding protein [38] . In contrast to retinol, serum β-carotene levels and other fat-soluble nutrients increase during the third trimester of pregnancy [16, 18-20, 23, 24] .
In some populations, poor nutritional status and low dietary intake of vitamin A are also likely to contribute to the decline in serum retinol during pregnancy. As can be seen from table 3, the largest percentage declines in serum retinol between the first and third trimester, and among the lowest mean serum retinol levels in the third trimester, were reported in women from low socioeconomic communities in India [23, 38] . In a malnourished rural population in Indonesia, 23% of pregnant women had serum retinol levels below 10 µg/dl [26] . In a US population of low-income pregnant women who were not taking vitamin supplements, 33% had serum retinol below 20 µg/dl [37] . Several other studies have shown an association between low socioeconomic status and low serum retinol levels in pregnancy [39] [40] [41] [42] [43] [44] .
Vitamin A in pregnancy: impact on maternal and newborn outcomes
Until recently, little attention was paid to vitamin A status in women during pregnancy. Initially the focus was on improving maternal vitamin A status as a means of improving vitamin A status in infancy and early childhood [8] . However, the recently reported finding of a substantial reduction in maternal mortality of a cohort of women in Nepal following supplementation with vitamin A or β-carotene [45] has led to a renewed interest in the role of vitamin A in the health of women during pregnancy and the post-partum period. These findings have raised a number of questions: Is there evidence of vitamin A deficiency in women during pregnancy? What are the health consequences of such deficiency? What is the evidence for important health benefits from vitamin A supplementation during pregnancy for the women and the newborn? Should vitamin A supplementation during pregnancy be recommended on a routine basis in populations with evidence of maternal vitamin A deficiency? Do we know enough about the extent of maternal vitamin A deficiency in different populations around the world to plan such interventions?
Maternal nutrition and health

Maternal vitamin A status: Serum retinol
Serum retinol declines during pregnancy to reach a nadir in the third trimester, followed by a rapid increase postpartum. Contributing to this decline are both hemodilution from an expanding blood volume as pregnancy progresses and inadequate intake of vitamin A. The frequency and extent of the decline are greater in women of low socioeconomic status; however, the functional significance of this decline in serum retinol during pregnancy is unclear. A modest reduction in serum retinol levels during pregnancy that is not associated with symptoms of vitamin A deficiency does not necessarily indicate reduced vitamin A stores and may be of no significance for the health of the woman and her infant [27] . However, as will be noted in the following sections, night-blindness is more common in the third trimester of pregnancy [46] , corresponding with the period when serum retinol concentrations are lowest. Furthermore, the decline in serum retinol levels during pregnancy can be reduced or stopped by treatment with vitamin A.
Maternal night-blindness
Night-blindness is the inability of individuals who have normal vision during daylight to see as the sunlight recedes in the evening. This poor adaptation to darkness occurs when there is a decreased production of rhodopsin, a vitamin A-dependent photosensitive pigment in the rod cells of the retina. Normally the rod cells are stimulated by dim light, allowing individuals to adapt to darkness and develop scotopic or night vision. In vitamin A deficiency, the reduced rhodopsin level results in a delayed visual adaptation to darkness, or even an inability to see at night if the deficiency is sufficiently severe [47] . The condition has been well recognized in children in developing countries, where it has been associated with an increased risk of childhood morbidity and mortality [48, 49] . In children night-blindness is an early indicator of vitamin A deficiency, and a history of night-blindness has been demonstrated to be a specific and sensitive indicator of low serum retinol levels [50] . In contrast, little attention has been paid to nightblindness in women of reproductive age [51, 52] .
There are several clinic-based reports of nightblindness or impaired dark adaptation in pregnant women who were likely to have an inadequate dietary intake of vitamin A. Birnbacher in 1927 (cited in Oomen [53] ) described an epidemic of night-blindness in postwar Vienna from 1920 to 1924. He observed that "pregnant women become night blind by preference towards the end of their term; in no case (of 30) was xerosis present; their nutritional state was satisfactory generally." There was a further report of night-blindness in pregnant women in Newfoundland and Labrador, Canada, in 1930 [54] . The condition appeared late in pregnancy and disappeared spontaneously after delivery. The investigator also noted that "three large tablespoon doses of cod oil" relieved the symptoms in one case within three days. In 1936, Edmund and Clemmesen [55] observed that 25 of 50 pregnant Danish women had dark dysadaptation that improved following an intramuscular injection of 40,000 IU of vitamin A. Ricketts in Ohio, USA, in 1939 reported two cases of vitamin A deficiency in pregnancy with night-blindness [56] . In 1940, Williams et al. [57] reported that 62% of 123 pregnant women examined in Philadelphia, USA, had vitamin A intakes below the recommended levels and that 35% had abnormal dark-adaptation times. The dark-adaptation time decreased in 21 of 28 women, who initially had abnormal dark-adaptation times, following 20,000 IU of vitamin A daily for one week. The review of vitamin A requirements of humans by Rodriguez and Irwin [58] provides more details of these early clinical studies. What is clear from these reports is that nightblindness in pregnancy was observed in Europe and the United States in the 1930s and 1940s but had apparently disappeared by the 1950s.
Further reports of night-blindness in pregnancy did not appear in the literature until 1966, when Dixit observed that 77 of 203 pregnant women examined in a clinic in Maharashtra, India, reported nightblindness during their current or previous pregnancies, mainly in the third trimester [46] . The condition spontaneously resolved soon after delivery, corresponding to a time when serum retinol rises rapidly (see table 3 ). Furthermore, the symptoms were temporarily relieved by an intramuscular injection of vitamin A. In 1969, Mandal et al. observed that 4.6% of women admitted to obstetric wards in West Bengal, India, reported being night blind [59] .
There are few reports of population-based surveys to assess the extent of night-blindness in pregnant and lactating women in developing countries. A survey of currently pregnant women from five districts in Sri Lanka [41] reported a prevalence of night-blindness at some time during pregnancy ranging from 0.6% to 2.8%. In contrast, a very high prevalence of any nightblindness (52%) during their previous pregnancy was reported by women in Jumla, Nepal, a remote community with a documented very high prevalence of vitamin A deficiency in children and a very high infant mortality rate (Starbuck 1993, cited in Katz et al. [51] ). In the rural Terai region of Nepal, a cross-sectional study of pregnant and lactating women found that 8.1% of pregnant women were night blind at the time of interview, although 16.2% of the lactating women reported being night blind at some time during their preceding pregnancy [51] . Night-blindness has also been reported recently from Central Java, Indonesia, where 4.8% of the women in the placebo group of a trial of vitamin A and zinc supplements in pregnancy reported night-blindness during the seond or third trimester of pregnancy [30] .
In cross-sectional surveys in three provinces in southern Vietnam in 1999, the prevalence of nightblindness among women aged 15 to 49 years during their most recent pregnancy within three years of the interview was 1.5% in Ben Tre Province, 5.6% in Long An Province, and 10% in Quang Ngai Province [60] .
However, a lower prevalence of night-blindness (1.0%) in pregnant women was reported in a 1995 national vitamin A survey in Vietnam [61] . These different estimates of prevalence might relate to the way in which the information was collected in the two surveys.
In the three-province survey in Vietnam in 1999, women were asked for a detailed history of their most recent pregnancy, including whether they had ever experienced night-blindness, using local terms for the condition depending on the ethnic group being interviewed. In the national survey in 1995, all women with a preschool-aged child were questioned, and the estimate of night-blindness during pregnancy was based on those women who self-reported that they were currently pregnant at the time of interview. In addition, it was unclear whether local terms for nightblindness were used in these interviews. Since night-blindness is more frequent during the third trimester, it is likely that latter approach would record a lower prevalence than asking women if they had ever experienced night-blindness during their last pregnancy.
In a supplementation trial in Nepal, a trained village fieldworker, using a local term, asked women if they were night-blind. Reports of night-blindness were verified within a week by specially trained interviewers who asked more detailed questions about the symptoms and their effects on the women's activity. Seventy-nine percent of the histories of current night-blindness were verified by this method. Thus, it is likely that some of the variation in estimates of the prevalence of night-blindness between studies is related to the method used to collect the information. Finally, night-blindness will only be a useful indicator of maternal vitamin A deficiency if the condition is recognized in the community and there are locally meaningful terms to describe the symptoms.
A number of factors have been reported to be associated with night-blindness in women during pregnancy. Women of lower socioeconomic status are more likely to report night-blindness in pregnancy [51, 62] . Lower intakes of vitamin A-rich foods, either preformed vitamin A or provitamin A carotenoids, were also associated with night-blindness in pregnancy [61, 62] , although this effect was modified by season in Nepal, possibly related to variations in the availability of these vitamin A-rich foods in some seasons [62] . In the 1995 National Vitamin A Deficiency Survey in Vietnam, the prevalence of night-blindness was higher in women of reproductive age who had less education and was slightly higher in older women [61] . In addition, recent morbidity, such as abdominal pain, dysentery, diarrhea, or nausea, was associated with an increased risk of night-blindness in women from Nepal [62] .
Lower levels of serum retinol have been reported in women with night-blindness during pregnancy. In a case-control study of night-blindness in Nepal, the mean serum retinol in the women with nightblindness was 20.6 µg/dl, as compared with 29.4 µg/dl in the control subjects, and this difference was statistically significant (p < .001) [62] . Similarly, in a trial of vitamin A and zinc supplementation in Indonesia, 2.5% of the women reported they were night blind early in their second trimester. The mean serum retinol of the night-blind women was 20.2 µg/dl, as compared with 40.1 µg/dl in the women without night-blindness, and this difference was statistically significant (p < .001) [30] .
Night-blindness during pregnancy is associated with poor health and nutritional status and an increased risk of pregnancy complications. In Indonesia, a crosssectional study of pregnant women reported a significant positive association between hemoglobin levels, hematocrit, serum iron levels, and serum retinol levels [44] . In a multivariate analysis of these survey data, after confounding factors were controlled for, each 1 µg/dl increase in serum retinol predicted a 1.5 g/L increase in hemoglobin and a 0.48 L/L increase in hematocrit.
Given this association, it is not surprising that pregnant women who are night blind or xerophthalmic are more likely to be anaemic than are non-night-blind women. In India, xerophthalmic pregnant women had mean hemoglobin levels of 8.3 ± 0.3 g/dl, which was significantly lower (p < .001) than the mean hemoglobin of 10.8 ± 0.4 g/dl for non-xerophthalmic pregnant women [63] . In Nepal, pregnant women who reported being night blind had a significantly lower (p < .004) mean hemoglobin (8.9 g/dl) than women who were not night blind (9.6 g/dl) [62] . This association may be indirect because of the overall poorer nutritional status of night-blind women; however, the evidence of a response of hemoglobin levels to vitamin A supplementation in vitamin A-deficient pregnant women suggests an independent effect of vitamin A on utilization of iron [64] .
One study from Nepal reported that pregnant women who were night blind had significantly lower body weight, body mass index (BMI), arm circumference, and skinfold thickness than control women [62] . An earlier, small clinic-based study from Nigeria found that clinically malnourished pregnant women had lower BMI, arm circumference, and serum retinol levels than clinically normal pregnant women; however, the investigators did not report whether the malnourished women had experienced nightblindness. Other studies have found an association between low serum retinol and indicators of proteinenergy malnutrition in pregnant women [26, 65] . More research in different populations is needed to confirm this relationship between maternal vitamin A deficiency, including night-blindness, and maternal protein-energy malnutrition.
Recent maternal morbidity is associated with night-blindness of women of reproductive age, especially during pregnancy. In women of reproductive age in Vietnam, there was a fourfold increase in the odds of maternal diarrhea during the two weeks prior to the interview in the night-blind women in comparison with the non-night-blind women [61] . Similarly in a case-control study of risk factors for night-blindness in Nepal, women who were night blind were two to three times more likely to report diarrhea or symptoms of urinary or reproductive tract infections during the week prior to the interview than controls [62] . This association persisted when morbidity was included in a multivariable logistic regression model that controlled for the effects of intake of vitamin A-rich foods and socioeconomic status of the women. There is only limited information about the functional significance of vitamin A deficiency and in particular night-blindness in pregnancy and whether or not it is associated with an increased risk of maternal morbidity and mortality. There are no reports of cohort studies that have examined the relationship between maternal night-blindness during pregnancy and subsequent risk of pregnancy-related or other morbidities. The incidence of night-blindness was assessed by history in 9,932 women in Nepal who participated in the Nepal Nutrition Intervention Project-Sarlahi (NNIPS-2) trial of low-dose vitamin A and β-carotene supplementation before and during pregnancy. Among the women in this trial reporting night-blindness, the death rate was 25.6/1,000, as compared with 3.4/1,000 in non-night-blind women, a 7.5-times higher risk of maternal death (95% CI, 3.06-18.27) [66] . However, from this very brief report, it is not clear whether this comparison is restricted to the placebo group and whether the effect is independent of other health and nutrition risk factors for maternal deaths present in the study population.
Impact of supplementation on maternal vitamin A status
There are several early reports of an impact of vitamin A supplementation on serum retinol levels in pregnancy. A semilongitudinal observational study in 1943 in London of serum retinol levels during pregnancy noted that women taking vitamin A supplements had higher levels of serum retinol throughout pregnancy than women not taking supplements [15] . Nonetheless, the usual pattern of a decline in serum retinol as the pregnancy progressed was observed in both groups of women.
In 1947 in New York, a controlled trial examined the impact on serum retinol levels of daily supplements, starting in the middle of the second trimester, with 10,000 IU of vitamin A (n = 122) or the equivalent dose of β-carotene (n = 123), versus no treatment (n = 93). Supplementation resulted in significantly (p < .001) higher levels of serum retinol by the ninth month of pregnancy in both the vitamin A and the β-carotene treatment groups (36.8 µg/dl), in contrast to the control group (27.9 µg/dl) [67] . This intervention did not affect the level of serum retinol in infant cord blood, which remained lower than the maternal serum retinol levels in all treatment groups. Briefly, the serum retinol was 21.9 µg/dl in the control group, 19.8 µg/dl in the vitamin A-treated group, and 21.0 µg/dl in the β-carotene-treated group [67] .
A small controlled trial of vitamin A supplementation in 29 pregnant Asian women in London revealed a significant (p < .05) increase in maternal serum retinol at delivery and a nonsignificant increase in infant cord serum retinol in the vitamin A-supplemented group [29] . The women selected for this trial had a serum retinol level <35.4 µg/dl at 28 weeks of gestation. The supplementation with 8,000 IU of vitamin A started at 30 weeks of gestation and continued until delivery. The serum retinol in the vitamin A-treated group (n = 14) was 37.7 µg/dl, in comparison with 28.6 µg/dl in the control group (n = 15) [29] .
In India, a controlled trial of daily supplements with 6,000 IU (1,800 RE) of vitamin A, administered to 202 pregnant women at different stages of pregnancy and for different durations, revealed that supplementation for more than 12 weeks was needed to prevent the decline in serum retinol levels at 34 to 38 weeks of gestation [68] . Serum retinol was 29.5 µg/dl in the control group at 34 to 38 weeks (n = 39), 30.1 µg/dl in women supplemented for 8 to 10 weeks (n = 5), and 36.1 µg/dl in women supplemented for more than 12 weeks (n = 29). This finding might reflect the severity of the maternal vitamin A deficiency in this population, which required more than 12 weeks of vitamin A supplements for correction. However, the weak design of this trial leaves chance also as a possible explanation for these variations in serum retinol following different durations of supplementation.
A further analysis of data from 30 women in the trial who had four serial blood measurements during pregnancy suggested that only women with a plasma retinol less than 30 µg/dl before 20 weeks of gestation showed a significant increase in plasma retinol during pregnancy when supplemented with vitamin A [69] . In this trial, the infant cord serum retinol levels were higher in the vitamin A-supplemented group (19.5 µg/dl for 8 to 12 weeks of supplementation, and 23.2 µg/dl for more than 12 weeks of supplementation) than in the control group (13.5 µg/dl). However, this difference was only significant in those women who were supplemented for more than 12 weeks [68] . This response of infant cord serum retinol to supplementation with vitamin A might also reflect the severity of maternal vitamin A deficiency in this population. Night-blindness was not assessed in the pregnant women who participated in this trial.
In Indonesia in 1992, a double-blind, placebo-controlled trial, using a factorial design, examined the impact of vitamin A and iron supplementation, starting at 19 weeks of gestation and continuing for 8 weeks, on serum retinol and indicators of iron status [64] . The baseline serum retinol for all treatment groups in this study was 30.9 µg/dl. During the 8 weeks of treatment, there was an increase in serum retinol (after adjustment for change in the placebo group) of 5.7 µg/dl in the women treated with vitamin A alone, and of 7.14 µg/dl in the group treated with vitamin A and iron. Symptoms of night-blindness in the women participating in the trial were not monitored.
A further trial in Indonesia conducted from 1995 through 1997 examined the impact of vitamin A and zinc supplementation on maternal sepsis and vitamin A status, using a double-blind, placebo-controlled, 2 × 2 factorial design [30] . The trial included 2,173 pregnant women with an average gestation of 12.5 weeks at enrolment. Women were individually randomized to one of four treatment groups: a daily dose of 2,400 RE of vitamin A, a daily dose of 20 mg of zinc, the same daily dose of both zinc and vitamin A, or a placebo with no vitamin A or zinc. A prospective monthly surveillance system was used to detect nightblindness in the pregnant women participating in the trial. Compliance with the daily supplements was high in this trial, with an average of 81% of distributed capsules being consumed by trial participants. At baseline before treatment, when the women were in their second trimester of pregnancy, 2.1% (23/1,089) of the women in the vitamin A-treated group and 2.9% (31/1,084) of those in the non-vitamin A -treated group reported experiencing night-blindness. The women reporting night-blindness had a significantly lower mean serum retinol (20.2 ± 13.97 [SD] µg/dl) than the non-night-blind women (40.1 ± 13.92
[SD] µg/dl).
Vitamin A significantly reduced the percentage of women reporting night-blindness during the second and third trimesters of pregnancy from 6.3% (68/1,084) in the women not treated with vitamin A to 0.8% (9/1,089), an 87% reduction in the risk of night-blindness (RR = 0.13; 95% CI, 0.07-0.26) [30] . In this trial, a subgroup of 846 women had consented to have serial blood samples collected in each trimester and six weeks postpartum. There were no significant differences in the baseline serum retinol levels of these women between treatment groups, and the mean serum retinol for all groups combined was 38.2 ± 13.55 (SD) µg/dl.
At baseline the percentage of women with serum retinol less than 30 µg/dl was higher in the vitamin A-treated group (31.5%) than in the nonvitamin A-treated group (26.1%). However, in the third trimester the percentage of women with serum retinol less than 30 µg/dl was lower in the group treated with vitamin A (25.1%) than in the group not treated with vitamin A (34.5%). In contrast, the percentage of women with serum retinol less than 30 µg/dl was only slightly lower in the group treated with zinc (28.7%) than in the group not treated with zinc (30.7%). Furthermore, the mean serum retinol was higher in the group treated with vitamin A (40.5 µg/dl) than in the group not treated with vitamin A (37.0 µg/dl) [30] .
The impact of vitamin A and β-carotene supplements on maternal night-blindness was examined in a large, community-based, group-randomized, placebo-controlled trial conducted in Nepal between 1994 and 1997 [70] . In this trial, 29,000 women of childbearing age from 171 wards were randomized to one of three treatment groups receiving weekly supplementation with 7,000 µg retinol equivalents (23,000 IU) of vitamin A, or β-carotene, or a placebo with no vitamin A. Night-blindness was assessed by prospective weekly surveillance during pregnancy and by recall at three and six months postpartum. The supplementation was continued over a period of three years, during which 9,932 woman who were pregnant for the first time were recruited into the trial.
Vitamin A significantly reduced the percentage of women reporting night-blindness during pregnancy from 10.7% in the control group to 6.7%, a reduction of 38% in the risk of night-blindness (RR = 0.62; 95% CI, 0.45-0.85). In contrast, β-carotene had less impact, with a nonsignificant 17% reduction in the risk of night-blindness (RR = 0.83; 95% CI, 0.45-1.11). When the analysis was restricted to women who took more than 95% of the supplements starting one month before conception until the end of pregnancy, vitamin A reduced the incidence proportion of verified nightblindness by 67% (RR = 0.33; 95% CI, 0.18-0.59); however, there was little impact of treatment with β-carotene.
There was no impact of vitamin A on night-blindness when compliance was 65% or less of the weekly supplements. Vitamin A, but not β-carotene, significantly reduced the incidence proportion of nightblindness at three and six months postpartum. For example, at three months postpartum, the incidence proportion of night-blindness was 11.3% in the control group, 4.3% in the vitamin A-treated group, and 8.7% in the β-carotene-treated group. This represents a 62% reduction in night-blindness with vitamin A treatment (RR = 0.38; 95% CI, 0.26-0.55) and a 23% reduction with β-carotene treatment (RR = 0.77; 95% CI, 0.57-1.04).
A possible explanation for the lower impact of vitamin A supplementation on night-blindness in the trial conducted in Nepal, in comparison with the trial in Indonesia, might be due to the severity of the vitamin A deficiency in the women in Nepal. The incidence of night-blindness in the women in the control group in Nepal was much higher (10.7%) [70] than in the placebo group in the trial in Indonesia (4.8%) [71] . In addition, the dose of vitamin A was higher in the Indonesian trial (16,800 µg RE of vitamin A) than in the Nepal trial (7,000 µg RE of vitamin A per week) and was delivered more frequently (daily versus weekly supplementation). Further studies are needed to determine the optimal dose, duration, and frequency of supplementation with vitamin A during pregnancy to reduce night-blindness and the steep decline in serum retinol during the third trimester of pregnancy.
Vitamin A and maternal anemia
Evidence has accumulated over several decades from studies in both adults and children of a relationship between vitamin A deficiency and iron-deficiency anemia [30, 72] . Hodges et al. [73] in 1971 conducted a small trial in which they observed moderate anemia in volunteers who had very low intakes of vitamin A for about one to two years. Furthermore, this anemia did not respond to treatment with iron but did respond to treatment with vitamin A. This stimulated them to perform a reanalysis of nutrition surveys conducted by the Interdepartmental Committee on National Defense (ICNND) in the 1960s.
Using an ecological study approach, they examined the relationship between vitamin A status and hemoglobin in nonpregnant and nonlactating women from eight developing countries where dietary vitamin A intake was low. They observed a linear relationship between mean plasma vitamin A and mean hemoglobin levels (r = 0.78, p < .05), but no relationship between iron intake and hemoglobin. In another observational study at the Institute of Nutrition of Central America and Panama (INCAP) in Guatemala, Mejia et al. [73] reanalyzed cross-sectional nutrition surveys and found a significant positive correlation between hemoglobin and plasma retinol in older children (5 to 12 years) but not in younger children (1 to 4 years). In all age groups, there was a positive correlation between plasma retinal and iron. A significant positive correlation between plasma retinal and iron was observed in children with an adequate dietary intake of iron, but this correlation was not found if the iron intake was inadequate.
These observational studies prompted a series of trials to evaluate the impact of vitamin A supplementation on iron status or iron-deficiency anemia in children [52, [74] [75] [76] [77] [78] [79] . Two of these trials delivered the vitamin A through fortification [52, 76] , two used daily low doses of vitamin A [77, 79] for two weeks to two months, and the other two trials used single high doses of vitamin A [74, 78] . All the trials reported either a reduction in anemia or improved iron status following treatment with vitamin A, although the impact appeared to be greater following fortification or daily low doses of vitamin A in comparison with the single high dose of vitamin A.
In contrast, there have been few trials of the impact of vitamin A supplementation on iron status or anemia in pregnant women. Panth and associates [68] from India reported a trial of supplementation of pregnant women with 1,800 RE of vitamin A daily for six weeks or longer. There was a significant increase in hemoglobin restricted to women from 26 to 28 weeks of gestation. However, this trial is difficult to interpret. The description of the methods leaves uncertainty as to whether or not the interventions were blinded, and the design was complex, with recruitment of women into the trial at different stages of pregnancy, which clouds the interpretation of the results. In Indonesia, Suharno and colleagues [44] in a cross-sectional study observed that, after adjustment for confounders in a multivariable linear regression model, serum retinal concentration was significantly positively associated (p < .01) with hemoglobin, hematocrit, and serum iron levels in pregnant women.
Following these observations, Suharno et al. [64] conducted a randomized, double-blind, placebo-controlled trial of vitamin A and iron supplementation of pregnant women to assess the impact on nutritional anemia. The women were supplemented from 19 weeks of gestation for 8 weeks with daily doses of 2,400 RE of vitamin A, 60 mg of elemental iron, both vitamin A and iron, or a placebo. The largest response in hemoglobin was in the women receiving both vitamin A and iron supplements (12.78 g/L; 95% CI, 10.68-14.70); one-third of this response was attributable to vitamin A (3.68 g/L; 95% CI, 2.03-5.33) and two-thirds to iron (7.71 g/L; 95% CI, 5. 97-9.45) . At the end of the supplementation period, 84% of the placebo-treated women were anemic (hemoglobin ≤110 g/L), 65% of the vitamin A-treated women were anemic, 32% of the iron-treated women were anemic, but only 3% of the women treated with both supplements were anemic. Because there was no follow-up of the women in the trial, at or after delivery, it is not known how long the benefits of supplementation lasted.
A similar beneficial effect of vitamin A and β-carotene supplements on iron-deficiency anemia in pregnant women and their newborns has been briefly reported from Nepal [79] . In this doubleblind, controlled trial, women of childbearing age were group-randomized to one of three treatment groups receiving weekly supplements of 7,000 µg RE (23,000 IU) of vitamin A, β-carotene, or a placebo with no vitamin A. Clinical studies were completed on approximately 10% of the pregnant women participating in the trial between September 1994 and June 1996. The analyses reported were from 978 pregnant women, 766 postpartum women, and 728 newborn infants. The results are summarized in table 4. There appears to be a reduction in iron-deficiency anemia in vitamin A-and β-carotene-treated pregnant women and a smaller reduction in postpartum women. The proportion of infants with hemoglobin less than 11 g/dl was also lower in the vitamin A-or β-carotene-treated groups.
The effects of treatment with vitamin A and β-carotene on iron-deficiency anemia were modified by hookworm (Ancylostoma duodenale) infection. All three groups had a high prevalence of hookworm (77%). In the women without hookworm, irondeficiency anemia was 46% and 27% lower in the vitamin A and β-carotene treatment groups, respectively, in comparison with the placebo group. There were only small differences in iron-deficiency anemia between treatment groups in those women infected with hookworm.
These preliminary results suggest that vitamin A reduced anemia during and after pregnancy, but the effect was mainly on mild rather than severe anemia. There was also a slight reduction in the percentage of infants with low hemoglobin (<11 g/dl). Serum ferritin was increased by treatment with vitamin A and β-carotene. The effects were modified by hookworm infection. A limitation of the study in terms of applying the results for programs is the prolonged supplementation prior to pregnancy and uncertainty as to the extent of the benefits from more restricted supplementation during pregnancy linked to antenatal care programs.
Overall, the evidence from these studies indicates important benefits for malnourished women from supplementation with vitamin A during pregnancy in terms of reduced nutritional anemia.
Vitamin A supplementation and maternal sepsis
Relatively few studies have examined the relationship between vitamin A status and the risk of puerperal fever and sepsis, or assessed the impact of vitamin A in preventing these conditions. A series of studies conducted during the period from 1920 to 1940 examined the role of vitamin A as an "antiinfective" therapy for specific diseases, including puerperal fever [80] . Much of the research during this period was pioneered by Edward Mellanby, a Professor of Pharmacology from the University of Sheffield, and Harry N. Green, a physician also from Sheffield.
Based on a series of animal experiments in which they observed increased rates of infection in vitamin A-deficient animals, they theorized that "vitamin A plays a significant part in raising the bodily resistance to infection" [80] . In 1929, they conducted a small preliminary trial of cod liver oil in the treatment of puerperal fever. A much lower case fatality rate of 28% (5/18) was observed in women with puerperal sepsis due to hemolytic streptococcal septicemia who were treated with cod liver oil, in contrast to a case fatality rate of 92% in a historical control group of untreated women [81] . This study prompted them to conduct a trial of cod liver oil as a prophylactic agent against puerperal sepsis [82] . In this study, 550 pregnant women attending antenatal care were alternatively assigned to either treatment with 1 ounce of cod liver oil daily during the final month of pregnancy or no treatment. Puerperal sepsis was defined by a body temperature higher than 100˚ F (38˚C) on two occasions between the end of the first day and the end of the eighth day postpartum. Treatment with cod liver oil reduced the incidence proportion of puerperal sepsis from 4.7% (13/275) in the control group to 1.1% (3/275). There was also a significant reduction in the incidence of puerperal pyrexia (temperature >99˚ F on one or more days after the first day until discharge) from 30.9% (85/275) in the control group to 19.2% (53/275) in the cod liver oil-treated group [82] . Similar findings of a 60% reduction in the incidence of puerperal sepsis were also reported from Edinburgh in 1931 [83] . The advent of the sulfa antibiotics may have reduced interest in the effect of vitamin A as an antiinfective treatment. In 1936, a trial of sulfanilamide [80] reduced mortality from puerperal fever from 22% to 8%.
The relationship between vitamin A and puerperal sepsis was not examined again until a cohort study conducted in Tennessee, USA, in 1954 reported an increased risk of puerperal fever and sepsis in women with low serum retinol levels in the second and third trimesters of pregnancy [16] . The role of micronutrient supplements in preventing puerperal sepsis was examined in a community-based trial [84] conducted in Indonesia from 1995 through 1997.
As previously mentioned, the impact of zinc and vitamin A on puerperal sepsis was examined in a community-based, individually randomized, placebocontrolled trial using a factorial design with four daily treatments of either vitamin A (2,400 RE), 20 mg of zinc sulfate, the same dose of vitamin A and zinc, or a placebo. All treatments were in identical opaque gelatin capsules, prepacked with study number, and sequentially assigned following consent of the women participating in the trial. Newly pregnant women from a district in Central Java, Indonesia, were identified through a surveillance system involving monthly visits to 28,000 households. Women were enrolled if their pregnancy was identified within 120 days of their last menstrual period and a urine-sample pregnancy test was positive.
Trained fieldworkers who recorded body temperature and collected symptoms daily for two weeks postpartum detected maternal postpartum infections. Puerperal sepsis was defined as a body temperature 38°C or higher on at least one day between the end of the first day and the fourteenth day postpartum. The initial 680 women enrolled in the trial had their maternal postpartum sepsis outcomes recorded. Baseline characteristics for these women were similar between all treatment groups. There was a high level of compliance, and the trial participants consumed an average of 81% of the distributed capsules. Postpartum feverishness (defined as two reports between day 1 and day 14 postpartum) was reported by 12.0% (17/142) of the placebo-treated women, and 11.3% (16/142) had an elevated body temperature (38 0 C or higher) on at least one postpartum day.
Treatment with vitamin A reduced the incidence proportion of episodes of elevated body temperature 38° C or higher on at least one postpartum day, from 9.3% (25/268) to 2.8% (7/251) in the control group. This represents a 70% reduction in puerperal sepsis in the vitamin A-versus non-vitamin A-treated women (RR = 0.30; 95% CI, 0.13-0.68). There was a 30% reduction in puerperal sepsis in women treated with zinc, but this was not significant (RR = 0.70; 95% CI, 0.37-1.47). The impact of vitamin A alone versus a placebo (RR = 0.21; 95% CI, 0.06-0.70) was similar to that of vitamin A and zinc versus a placebo (RR = 0.29; 95% CI, 0.10-0.84). These results, combined with those of the trial in Sheffield in 1931, strongly suggest that low-dose vitamin A given during the second and third trimesters of pregnancy can substantially reduce the risk of postpartum infections in populations of vitamin A-deficient women.
Vitamin A supplementation and maternal mortality
To date only a single trial has been published examining the impact of vitamin A and β-carotene in preventing maternal mortality [45] . This large, community-based, group-randomized, placebo-controlled trial was conducted in Nepal from April 1994 through September 1997. Women of reproductive age living in a ward (a local administrative area) were randomly assigned to one of three supplementation interventions: a single weekly oral supplement of 7,000 µg retinol equivalents of vitamin A, 7,000 µg retinol equivalents of β-carotene, or placebo. The supplements were provided over a period of 3½ years to 44,646 women, of whom 20,119 became pregnant once and 2,070 became pregnant twice during this period. Trained female fieldworkers delivered the supplements to trial participants and collected health information during weekly household visits.
The main trial outcomes were all-cause mortality in women during pregnancy up to 12 weeks postpartum (pregnancy-related mortality) and mortality during pregnancy to six weeks postpartum, excluding deaths apparently related to injury (maternal mortality ratio). Pregnancy-related mortality occurred at a rate of 704 per 100,000 pregnancies in the placebo group (51/7,241) , 426 in the vitamin A group (33/7,747) , and 361 in the β-carotene group (26/7,201) . These represent preventive effects, expressed as relative risks, of 0.60 (95% CI, 0.37-0.97) for vitamin A treatment and 0.51 (95% CI, 0.30-0.86) for β-carotene treatment. The maternal mortality was 645 per 100,000 live births in the placebo group (42/6,670) , 407 in the vitamin A group (29/7,074) , and 361 in the β-carotene group (23/6,643) . The maternal mortality for vitamin A and β-carotene combined was 385 per 100,000 live births, giving a preventive effect with relative risk of 0.60 (95% CI, 0.39-0.93). The impact of each supplement alone on the maternal mortality ratio was not significant.
This trial was well designed and carefully executed. The investigators demonstrated that the vitamin A and β-carotene interventions did affect serum retinol and β-carotene concentrations in the treated women. In the women treated with vitamin A, there was an increase in serum retinol but no increase in serum β-carotene, whereas in the women treated with β-carotene, there was a smaller increase in serum retinol as well as an increase in serum β-carotene. There was an adequate sample size of 44,000 women and 22,000 pregnancies to examine the two a priori formulated hypotheses.
The limitations of the trial have been highlighted in an editorial [85] and correspondence about the study [86] [87] [88] . These concerns include some uncertainty about the impact of differential loss to follow-up on the numerators and denominators used in the analyses, the appropriateness of combining the vitamin A and β-carotene groups in analyses, the relevance of the main trial outcome, and the relevance of the findings to plausible supplementation programs.
One hundred fifty-seven women were lost to follow-up during the postpartum period (70 in the vitamin A group, 43 in the β-carotene group, and 44 in the placebo group). If all of these women had died, the impact of treatment with vitamin A on mortality would have been underestimated. However, if the mortality rate in these groups were the same as the average in the study population, there would have been no change on the reported efficacies of the interventions. Given the size of the trial, the loss to follow-up seems remarkably small and is unlikely to have altered the overall conclusions of the trial that vitamin A and β-carotene supplements in vitamin A-deficient women have an important impact on maternal mortality.
In several analyses, the authors combined the vitamin A and β-carotene groups; however, several commentators questioned this approach [86, 87] . The biological mechanisms by which these supplements might affect maternal mortality are likely to be different. Improved vitamin A status from supplementation with either preformed vitamin A or β-carotene might reduce mortality through a reduced risk of sepsis and possibly reduced levels of severe anemia. The antioxidant properties of β-carotene may have resulted in reduced rates of severe preeclampsia. In addition, these interventions should have different effects on biochemical indicators of vitamin A status, as was observed in the trial in Nepal. There is likely to be sufficient overlap in the mechanisms by which these two forms of vitamin A could potentially affect maternal mortality to justify conducting analyses with combined groups, provided the effects are also examined in each treatment group individually. Nonetheless, the study did not have adequate power to examine whether there was a significant difference in the level of impact between the preformed vitamin A and the β-carotene supplements. Finally, the authors state that they had planned combined analyses of these supplementation groups from the outset of the trial [45] .
The investigators selected pregnancy-related mortality rather than maternal mortality as the primary endpoint for the trial. The later outcome is mortality restricted to the first six weeks following delivery and excludes deaths due to injuries and accidents. The investigators did attempt to determine the cause of death using a "verbal autopsy" method, although it was not clear whether this method had been validated in the study population. The investigators justified using an extended postpartum period for follow-up of 12 weeks because "maternal mortality related to malnutrition could extend beyond the conventional six weeks." However, this claim was not explained or justified by any supporting studies. The choice of trial outcome leaves open the possibility that the intervention resulted in a reduction in all-cause female mortality rather than an effect specific to maternal mortality [88] .
The verbal autopsy data revealed little impact of the interventions on direct obstetric causes of mortality, and the largest relative impact was on deaths due to injuries. These findings are hard to reconcile with known potential mechanisms of maternal mortality, although it is possible that reductions in nightblindness were associated with lower injury-related mortality in the treated women postpartum. In summary, the reasons for selecting the main trial outcome, rather than the more conventional maternal mortality outcome, are not well developed in the report of the trial. If a more conventional trial outcome had been chosen, the impact of the intervention would have appeared less certain. The inclusion of the verbal autopsy data did not contribute to clarifying the interpretation of the findings. The validity of the verbal autopsy method used was uncertain, and there was insufficient power to detect the impact of the interventions on cause-specific mortality.
Suggestions that the investigators should have completed subgroup analyses based on the results of the verbal autopsy [87] are not appropriate, since the investigators used the only valid analysis strategy, namely, an intention-to-treat analysis based on all deaths and pregnancies during the defined follow-up period and the a priori defined trial outcomes.
Lastly, the direct relevance of the trial findings for programs is unclear. Is the mortality-sparing effect of the interventions used in the trial only a consequence of their prolonged delivery starting prior to the onset of pregnancy? Supplementing all women of reproductive age with vitamin A is not a sustainable or plausible intervention in most countries with high levels of maternal vitamin A deficiency. Can the same impact be expected if the intervention is only provided during pregnancy through established health infrastructures used to deliver antenatal care services? Finally, it remains unclear which type of supplement, vitamin A or β-carotene, is more effective.
Despite these limitations, the NNIPS-2 trial has focused attention on the need to further examine the potential role of nutrition, especially improving vitamin A status, in preventing maternal mortality.
Vitamin A status of newborn
In most reports, infant cord blood serum retinol concentrations appear to be resistant to maternal supplementation with vitamin A during pregnancy [29, 35, 63, 67] . However, in populations with more severely vitamin A-depleted mothers of low socioeconomic status, oral supplementation with 30,000 IU of vitamin A during the last trimester of pregnancy resulted in higher infant serum retinol levels [19, 69] .
It should be noted that fetal serum retinol concentrations are relatively independent of fetal liver vitamin A concentrations unless the liver stores are very low [89] . Thus, failure to alter cord blood concentrations may be masking substantial improvements in newborn liver vitamin A concentration, which are known to be low in newborns in many developing countries [40, 89] .
Birthweight and duration of gestation
Several trials of vitamin A supplementation during pregnancy have reported no important impact of vitamin A supplements on birthweight [29, 67, 68, 84, 90] . This finding is not surprising, given the homeostatic mechanisms to support transfer of vitamin A to the fetus and the mechanisms to maintain fetal serum retinol concentrations [89] . Furthermore, vitamin A has been reported to have only a minor impact on postnatal infant growth, which is mainly limited to children with evidence of severe vitamin A deficiency.
A trial of vitamin A supplementation in HIV-positive pregnant women in South Africa has, however, reported a reduced rate of preterm delivery in vitamin Asupplemented women (17.4% in the placebo group to 11.4% in the vitamin A-treated group) [91] . It is possible that vitamin A will have different effects on gestation and birthweight in different populations. More work is needed to characterize the circumstances in which vitamin A supplementation might have a useful impact on birthweight and gestation
Neonatal morbidity and mortality
It is well established in industrialized countries that preterm infants have limited stores of vitamin A and that without supplementation with vitamin A, their suboptimal vitamin A status may persist for many months [8] . It has also been demonstrated that these infants have an increased risk of bronchopulmonary dysplasia and that this is prevented by appropriate postnatal vitamin A supplementation [92] . These observations have stimulated speculation that improving vitamin A status of newborn infants might have an impact on early respiratory illness frequently reported in infants in vitamin A-deficient populations.
Nonetheless, to date there have been no studies that examined the impact of maternal supplementation with vitamin A on neonatal morbidity or mortality. The NNIPS-2 trial [45] should eventually provide critical information about the impact of this intervention on neonatal survival in a vitamin A-deficient population.
Vertical transmission of human immunodefi ciency virus (HIV) in pregnancy
Higher rates of vertical transmission of HIV from mother to child have been observed in developing countries [93] , suggesting that either nutrition or differing breastfeeding practices may be an important influence [94] . Both pregnancy and HIV infection are known to be risk factors for vitamin A deficiency [95] . In addition, it is known that vitamin A plays an important role in immune function and in maintaining epithelial integrity of mucosal surfaces [95] . A detailed outline of the theories about why vitamin A may have a protective role against vertical transmission of HIV is beyond the scope of this review; however, it is well described by Semba [94] .
Semba et al. [95] undertook a study to determine whether vitamin A deficiency played a role in the vertical transmission of HIV in a group of pregnant women in Blantyre, Malawi. This prospective cohort study showed that serum vitamin A levels, measured at the first antenatal care visit, of the mothers with HIV-infected offspring were significantly lower than those of mothers whose offspring were not affected by HIV. Following adjustment for maternal percentage of CD4 lymphocytes, maternal age, and body mass index, multivariate logistic regression models produced an odds ratio of 0.56 (95% CI, 0.37-0.85) for mother-to-child transmission of HIV based on 0.45 µg/L increments in serum vitamin A. These authors estimated an attributable risk of vertical transmission of HIV of 0.25 for mothers with vitamin A levels below 0.70 µmol/L as compared with mothers with levels above 1.40 µmol/L. This study was limited by a low follow-up rate, with only 286 of an original 567 pregnant women being included in the study. The others were excluded because their infants had died, they were lost to follow-up, or they declined to provide blood specimens. Additional criticisms have related to the methods of assessing breastfeeding status and the nonuniform timing of the lymphocyte subset measurements [96] . Despite these limitations, the study results indicated the need for further research, given the potential cost-effectiveness of providing dietary vitamin A to pregnant women [96] .
A hospital-based cohort study [97] in Bangkok, Thailand, showed that lower levels of serum vitamin A and β-carotene are found in women with HIV than in controls. The reduction in the levels of these two nutrients was significantly correlated with the percentage of CD4 lymphocytes, CD4 count, and CD4/CD8 ratio. Subsequent research has suggested that a possible explanation for the observed lower vitamin A concentrations in pregnant women with HIV may be due to an acute-phase response rather than a reflection of lowered body stores of vitamin A [98] .
A study of two cohorts of pregnant women with HIV [99] showed no statistical association between maternal vitamin A levels in the third trimester and transmission of HIV. This study was conducted in the United States with third-trimester women from metropolitan New York and Los Angeles. However, as would be expected, vitamin A deficiency was uncommon among the pregnant women in this study from an industrialized country [96] .
Two moderately large randomized control trials failed to show any significant protective effect of vitamin A in preventing vertical transmission of HIV. The first of these studies was a large randomized control trial in Dar es Salaam, Tanzania. A total of 1,075 pregnant women between 12 and 27 weeks of gestation were assigned to one of four treatment groups: multivitamin supplements with vitamin A, multivitamin supplements excluding vitamin A, vitamin A alone (30 mg of β-carotene plus 5,000 IU of vitamin A), or a placebo. Multivitamins had significant protective effects on the risk of low birthweight, severe preterm birth, and small size-for-gestational-age, but no significant associations were observed for vitamin A [90] . Despite significant increases in CD4, CD8, and CD3 counts for women who consumed multivitamins, no such increase was observed for women consuming vitamin A alone [90] . No direct evaluation of vertical transmission of HIV was described in this study.
More recently, Coutsoudis [91] conducted a randomized, controlled trial of placebo or retinol (5,000 IU of retinyl palmitate and 30 mg of β-carotene) in a group of 728 HIV-infected pregnant women from Durban, South Africa, over a three-year period. This study also showed that vitamin A was not effective in reducing HIV vertical transmission in the women examined. Despite these findings, a lower rate of HIV transmission at 28 days and a lower risk of preterm deliveries were observed. A 47% decrease in HIV transmission was observed among 80 preterm babies; however, wide confidence intervals were observed for the intervention (prevalence, 17.9%; 95% CI, 3.5%-32.2%) and control groups (prevalence, 33.8%; 95% CI, 19.8%-47.8%). A high response rate of 91.7% was achieved in this study, although the sample size may have limited the power to detect a significant difference. The results of other trials presently being conducted in Africa should allow pooling of the results to provide additional power to examine whether vitamin A has a protective effect against vertical HIV transmission. Further research may be considered on HIV transmission in preterm infants in view of the high rate of preterm deliveries in HIV patients [91] . This topic is also covered by Coutsoudis in this issue [100] .
Conclusions and recommendations
Maternal health and nutrition
Maternal vitamin A status
Vitamin A deficiency, as evidenced by night-blindness and low serum retinol levels, especially in the third trimester, is most probably common in populations known to have vitamin A deficiency in children. More research is needed to establish the extent of the problem in populations in developing countries and to characterize the changes in serum retinol and vitamin A status during pregnancy in well-nourished populations, as well as in populations with inadequate intakes of vitamin A.
There is evidence that daily or weekly low doses of vitamin A supplements, starting in the second or even third trimester, can reduce the severity of the decline in maternal serum retinol levels during late pregnancy and reduce symptoms of night-blindness. Women who have night-blindness should be treated with vitamin A using previously recommended doses. Effectiveness trials of vitamin A supplementation or dietary interventions should be considered to identify the most appropriate interventions for future programs to control vitamin A deficiency in women of reproductive age, especially women who are pregnant.
Maternal anemia
There is good evidence that vitamin A supplementation, when combined with iron supplementation and treatment for intestinal parasites, can reduce the levels of mild to moderate nutritional anemia by approximately 30%. Further research would be warranted in populations with different disease profiles, for example, women from endemic malarious areas. In addition, research is needed to compare the effectiveness of increases in dietary vitamin A and iron intakes versus supplements with these nutrients on nutritional anemia in women of reproductive age and during pregnancy.
Maternal sepsis
Preliminary studies and research conducted in the 1930s suggested that vitamin A had a powerful effect on reducing the risk of postpartum sepsis in women. This is likely to be an important intervention for women who deliver in contaminated environments and who are vitamin A deficient. More research is required to confirm these findings and to identify the minimum size and duration of doses needed to provide this protection. There is enough evidence to consider effectiveness trials of vitamin A supplements linked to antenatal care programs to assess the impact on maternal postpartum sepsis. The role of vitamin A in reducing sepsis following delivery by cesarean section also needs evaluation.
Maternal mortality
The findings from the NNIPS trial in Nepal provide strong evidence that vitamin A deficiency is an important factor contributing to the immediate causes of maternal mortality. This trial needs to be replicated in other populations. However, it should be recognized that these replication trials are likely to take place in populations with severe malnutrition and vitamin A deficiency and most probably with low levels of health care services for pregnant women and are likely to represent a maximum impact of the intervention.
Newborn nutrition and health
Given the strong homeostatic mechanisms to maintain fetal levels of serum retinol and the modest increment in requirements for vitamin A during pregnancy, it is likely that benefits of vitamin A supplementation in pregnancy for the newborn will be limited to populations with severe maternal vitamin A deficiency.
